Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Astrana Health
ASTH
Astrana Health
Policy And Integration Risks Will Hamper Prospects But Enable Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
07 May 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$35.00
14.5% undervalued
intrinsic discount
16 Aug
US$29.94
Loading
1Y
-37.4%
7D
4.4%
Author's Valuation
US$35.0
14.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$35.0
14.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-629k
4b
2014
2017
2020
2023
2025
2026
2028
Revenue US$4.5b
Earnings US$157.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
17.20%
Healthcare Services revenue growth rate
0.27%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$157.32m
Earnings '28
x
14.08x
PE Ratio '28
=
US$2.22b
Market Cap '28
US$2.22b
Market Cap '28
/
52.56m
No. shares '28
=
US$42.16
Share Price '28
US$42.16
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$34.63
Fair Value '25
